A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 22, 2011

Primary Completion Date

July 14, 2016

Study Completion Date

March 26, 2018

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Metformin

"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops."

DRUG

Placebo

"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops."

Trial Locations (5)

Unknown

London Regional Cancer Program, London

M5B 1N9

St. Michael's Hospital, Toronto

M5G 1X5

Mount Sinai Hospital, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

N8W 2X3

Windsor Regional Cancer Centre, Windsor

Sponsors
All Listed Sponsors
collaborator

Breast Cancer Research Foundation

OTHER

lead

Ozmosis Research Inc.

INDUSTRY